Microbiology Research Platform
Comprehensive resources on adhesins, bacterial attachment mechanisms, and microbial pathogenesis. Advancing our understanding of host-pathogen interactions through research, education, and interactive tools.
Understanding bacterial adhesion at the molecular level
Molecular mechanisms of bacterial surface proteins mediating attachment to host cells and tissues.
How adhesins facilitate bacterial colonization, invasion, and immune evasion in the host.
Development of novel therapeutic strategies targeting bacterial adhesion as alternatives to antibiotics.
Explore adhesin biology across bacterial species and clinical contexts
Research articles and reviews in bacterial adhesion biology
Urinary tract infections affect 150 million people annually. FimH, the mannose-binding adhesin at the tip of type 1 fimbriae, is the primary mediator of E. coli attachment to uroepithelial cells. Over the past decade, structure-based drug design has yielded potent FimH antagonists -- mannosides that compete with the natural receptor. Phase II clinical trials of oral mannosides show 70% reduction in recurrent UTI compared to placebo, without driving antibiotic resistance. This review covers the structural biology of FimH, the medicinal chemistry of mannoside analogs, and the clinical pipeline.
Curli fibers are functional amyloid structures produced by E. coli and Salmonella that serve dual roles: they provide structural integrity to biofilms and trigger innate immune recognition through TLR2 and the NLRP3 inflammasome. Recent cryo-EM structures reveal the CsgA subunit assembles into cross-beta sheets that resist protease degradation. Understanding curli biology is relevant to both infectious disease (biofilm-related infections) and autoimmunity (molecular mimicry with human amyloids in systemic lupus erythematosus).
Traditional vaccines target toxins or capsular polysaccharides, but adhesin-based vaccines aim to prevent colonization itself. FimH vaccines for UTI, PilE vaccines for meningococcal disease, and ClfA vaccines for S. aureus surgical site infections are all in clinical development. The advantage: anti-adhesin antibodies block the initial attachment step without killing the bacterium, reducing selective pressure for resistance. This review examines the rationale, preclinical evidence, clinical trial results, and challenges in adhesin vaccine development.
Interested in research collaboration, data access, or educational licensing? Contact our team.
Schedule a meeting with our team to discuss collaboration opportunities, educational use, or technical questions about bacterial adhesion research.